Dear Colleagues,

Here is the Daily Briefing for 28 July 2017. Any feedback would be most welcome.

Best wishes,

Faraz Kermani, Communications Manager (External Affairs)

**Health Services**

- **CQC boss heads for the exit: “I’ve always told it as it is”**
  (27/07/2017) (British Medical Journal)
  Rebecca Coombes talks to Mike Richards about UK hospital inspections and standards ahead of his retirement.

- **AMR**
  (27/07/2017) (The Guardian)
  Australian babies given antibiotics at some of the highest rates in the world
  The levels risk long-term side-effects and antibiotic resistance, which has been described by World Health Organisation as a ‘global emergency’.

- **Trust me on antibiotics, doctor – I’m a patient**
  (27/07/2017) (The Guardian)
  Evidence that finishing the course may fuel bacterial resistance will test our relationship with experts – and perhaps begin the healing process.

- **EU report: more evidence on link between antibiotic use and antibiotic resistance**
  (27/07/2017) (European Medicines Agency)
  The European Food Safety Authority, the European Medicines Agency and the European Centre for Disease Prevention and Control are concerned about the impact of use of antibiotics on the increase in antibiotic-resistant bacteria.

**Companies**

- **Celltrion Healthcare jumps 10% on debut in Seoul**
  (28/07/2017) (Financial Times)
  South Korea’s Celltrion Healthcare, the marketing affiliate of biosimilar maker Celltrion, jumped on its trading debut on Friday to become the second-largest company on the junior Kosdaq market.
Servier licenses GLPG1972 in osteoarthritis from Galapagos
(28/07/2017) (FirstWord Pharma)
Servier announces that it has exercised its option to develop novel osteoarthritis molecule GLPG1972/S201086 from Galapagos, thus obtaining global commercial rights outside the US.

GSK Plans Major R&D Overhaul
(27/07/2017) (PharmTech.com)
The pharma major aims to focus the majority of R&D capital on priority therapy areas and plans to cut approximately 30 R&D programmes.

TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan
(27/07/2017) (FirstWord Pharma)
Takeda’s rights include all potential indications for niraparib in Japan and rights excluding prostate cancer in South Korea, Taiwan, Russia and Australia.

Astellas Announces Wind-Down of Agensys Research Operations
(27/07/2017) (FirstWord Pharma)
The move is aimed to further refine its oncology strategy by expanding its investment in the research in new technologies and modalities and reducing its focus on Antibody-Drug Conjugate (ADC) research.

Policy

Obamacare repeal bill founders in Senate as McCain votes no
(28/07/2017) (Financial Times)
Senate Republicans have failed, by a single vote, to pass a bill to repeal Obamacare which contained measures that could have resulted in millions of Americans losing health insurance coverage and sharp, repeated rises in premiums.

CDC may face double jeopardy with Senate health bill
(27/07/2017) (STAT)
If Senate Republicans pass a version of their health reform bill, and if a current House GOP spending plan is enacted, it could spell double jeopardy the Centers for Disease Control and Prevention.

Specific Disease Areas

Cancer immunotherapy is a hot field, but a failed trial raises key questions
(27/07/2017) (STAT)
Only about one-third of cancer patients benefit from treatment with these new therapies.

R&D

Science ministers want Brussels to slim down research funding programme
(27/07/2017) (Science|Business)
The current system is so complex and fragmented that you need professional consultants to make sense of it, says Estonia’s science minister, Mailis Reps.

Clinical Trials

AstraZeneca lung cancer immunotherapy trial failure sends shares plunging
(27/07/2017) (STAT)
In the preliminary MYSTIC clinical trial results, the combination of checkpoint inhibitor Imfinzi and the CTLA-4 inhibitor tremelimumab failed to slow disease progression compared to chemotherapy.
**Brexit**

- **Athens and Milan throw names into EU medicines agency hat**
  
  (28/07/2017) (EurActiv.com)
  
  Around 20 countries across the bloc have already said they want to host the EMA, so competition will be tough and proceedings complicated.

**HTA**

- **ECRI Institute Releases White Paper on New Approach to Evidence-based Value Analysis**
  
  (27/07/2017) (KLTV 7 News)
  
  ECRI Institute’s new white paper shows value analysis leaders how to apply an analytic framework to the value analysis process to improve consistency and efficiency, and remove bias.

**Regulatory**

- **FDA Approves Eisai’s FYCOMPA (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures**
  
  (27/07/2017) (FirstWord Pharma)
  
  This is the first antiepileptic drug (AED) to apply FDA’s regulatory pathway of extrapolation for monotherapy use.

**Healthcare spending**

- **Lifesaving drugs caught up in ‘funding logjam’**
  
  (28/07/2017) (Irish Examiner)
  
  Nine new hi-tech drugs were recommended for approval by the HSE, subject to additional funding being provided.

**Big Data / Real World Data**

- **Novartis and Bayer among backers for European big data project**
  
  (27/07/2017) (PMLIVE Blogs)
  
  A European project to advance big data-driven cardiovascular research has launched with EU and pharma backing.